Vanda Pharmaceuticals
Trial Pipeline
An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
NCT07179055
Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder
NCT07221578
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
NCT07090161
Randomized Withdrawal Study in Patients With Schizophrenia
NCT06961968
Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia
NCT06953869
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
NCT06830044
A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
NCT06296966
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
NCT05648591
Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
NCT05361707
Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)
NCT04652882
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
NCT03838926
Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances
NCT03154697
Patient Registry of Blind Subjects With Sleep-related Problems
NCT01195558
Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient
NCT07223632
Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis
NCT07065773
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
NCT06138613
A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use
NCT06804603
Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy Volunteers
NCT05572281
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris
NCT04856917
Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety
NCT04800237
Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers
NCT04849559
WGS Analysis of COVID-19 Positive Patients
NCT04353401
Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia
NCT04127058
Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis
NCT02970968
Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents
NCT02776215
A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder
NCT03291041
Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis
NCT02651714
Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS
NCT02231008
An Observational Study to Investigate the Effects of Rapid Transmeridian Travel
NCT02560103
Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients
NCT01495169
A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects
NCT01402076
Relapse Prevention Study in Patients With Schizophrenia
NCT01291511
Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment
NCT01271387
Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia
NCT00254202
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 11 |
| Phase 3 | 9 |
| Phase 4 | 1 |
What the Pipeline for Vanda Pharmaceuticals Shows
According to the ClinicalTrials.gov registry, Vanda Pharmaceuticals is linked to 34 US clinical trials across every stage of research activity. Of those, 13 studies are currently recruiting — about 38% of the sponsor's indexed portfolio — and 18 are already marked complete, representing roughly 53% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Vanda Pharmaceuticals reports 10 late-stage studies (Phase 3 and Phase 4 combined) and 20 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Vanda Pharmaceuticals is Schizophrenia with 5 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.